Related references
Note: Only part of the references are listed.Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors
Gudbjorg Andresdottir et al.
DIABETES CARE (2014)
Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies
Roland E. Schmieder et al.
DIABETOLOGIA (2014)
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Dick de Zeeuw et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Changes in Diabetes-Related Complications in the United States, 1990-2010
Edward W. Gregg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
John J. V. McMurray et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Dick de Zeeuw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pablo E. Pergola et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
D de Zeeuw et al.
CIRCULATION (2004)
Share Paper
